Literature DB >> 12205295

Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice.

Simona Capsoni1, Sabina Giannotta, Antonino Cattaneo.   

Abstract

Phenotypic knockout of nerve growth factor (NGF) activity in transgenic anti-NGF mice (AD11 mice) results in a progressive neurodegenerative phenotype resembling Alzheimer's disease. In this article, we examine whether and how the progressive neurodegenerative phenotype of AD11 mice could be prevented or ameliorated by pharmacological treatments with NGF or the cholinergic agonist galantamine, at a relatively early phase of Alzheimer's disease-like neurodegeneration. We demonstrate that the neurodegeneration induced by the expression of anti-NGF antibodies in AD11 mice can be largely reversed by NGF delivery through an olfactory route.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12205295      PMCID: PMC129462          DOI: 10.1073/pnas.192442999

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

Review 1.  Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles.

Authors:  M M Mesulam
Journal:  Neuron       Date:  1999-11       Impact factor: 17.173

2.  Alzheimer disease is multifactorial and heterogeneous.

Authors:  K Iqbal; I Grundke-Iqbal
Journal:  Neurobiol Aging       Date:  2000 Nov-Dec       Impact factor: 4.673

3.  Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease.

Authors:  A Maelicke; E X Albuquerque
Journal:  Eur J Pharmacol       Date:  2000-03-30       Impact factor: 4.432

4.  The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease.

Authors:  M Fahnestock; B Michalski; B Xu; M D Coughlin
Journal:  Mol Cell Neurosci       Date:  2001-08       Impact factor: 4.314

Review 5.  On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis.

Authors:  R T Bartus
Journal:  Exp Neurol       Date:  2000-06       Impact factor: 5.330

Review 6.  Nerve growth factor signaling, neuroprotection, and neural repair.

Authors:  M V Sofroniew; C L Howe; W C Mobley
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

7.  Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice.

Authors:  S Capsoni; G Ugolini; A Comparini; F Ruberti; N Berardi; A Cattaneo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

8.  NGF mRNA is not decreased in frontal cortex from Alzheimer's disease patients.

Authors:  N Jetté; M S Cole; M Fahnestock
Journal:  Brain Res Mol Brain Res       Date:  1994-09

9.  Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain.

Authors:  C Russo; S Salis; V Dolcini; V Venezia; X H Song; J K Teller; G Schettini
Journal:  Neurobiol Dis       Date:  2001-02       Impact factor: 5.996

Review 10.  Nerve growth factor and Alzheimer's disease.

Authors:  S A Scott; K A Crutcher
Journal:  Rev Neurosci       Date:  1994 Jul-Sep       Impact factor: 4.353

View more
  45 in total

1.  Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures.

Authors:  Neil J Johnson; Leah R Hanson; William H Frey
Journal:  Mol Pharm       Date:  2010-06-07       Impact factor: 4.939

Review 2.  On the molecular basis linking Nerve Growth Factor (NGF) to Alzheimer's disease.

Authors:  Simona Capsoni; Antonino Cattaneo
Journal:  Cell Mol Neurobiol       Date:  2006-08-31       Impact factor: 5.046

3.  Molecular simulation of the binding of nerve growth factor peptide mimics to the receptor tyrosine kinase A.

Authors:  Marco Berrera; Antonino Cattaneo; Paolo Carloni
Journal:  Biophys J       Date:  2006-06-23       Impact factor: 4.033

4.  Acetylcholinesterase inhibitors rapidly activate Trk neurotrophin receptors in the mouse hippocampus.

Authors:  Henri Autio; Kert Mätlik; Tomi Rantamäki; Lothar Lindemann; Marius C Hoener; Moses Chao; Urmas Arumäe; Eero Castrén
Journal:  Neuropharmacology       Date:  2011-07-30       Impact factor: 5.250

5.  Progress in the development of new drugs in Alzheimer's disease.

Authors:  Antoine Piau; F Nourhashémi; C Hein; C Caillaud; B Vellas
Journal:  J Nutr Health Aging       Date:  2011-01       Impact factor: 4.075

6.  Galantamine alleviates inflammation and other obesity-associated complications in high-fat diet-fed mice.

Authors:  Sanjaya K Satapathy; Mahendar Ochani; Meghan Dancho; Laqueta K Hudson; Mauricio Rosas-Ballina; Sergio I Valdes-Ferrer; Peder S Olofsson; Yael Tobi Harris; Jesse Roth; Sangeeta Chavan; Kevin J Tracey; Valentin A Pavlov
Journal:  Mol Med       Date:  2011-07-01       Impact factor: 6.354

7.  Intranasal Delivery of a Caspase-1 Inhibitor in the Treatment of Global Cerebral Ischemia.

Authors:  Ningjun Zhao; Xiaoying Zhuo; Yujiao Lu; Yan Dong; Mohammad Ejaz Ahmed; Donovan Tucker; Erin L Scott; Quanguang Zhang
Journal:  Mol Neurobiol       Date:  2016-08-13       Impact factor: 5.590

Review 8.  Neurotrophic factors in neurodegenerative disorders : potential for therapy.

Authors:  Fabio Fumagalli; Raffaella Molteni; Francesca Calabrese; Paola Francesca Maj; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

9.  In the adult hippocampus, chronic nerve growth factor deprivation shifts GABAergic signaling from the hyperpolarizing to the depolarizing direction.

Authors:  Laura Lagostena; Marcelo Rosato-Siri; Mara D'Onofrio; Rossella Brandi; Ivan Arisi; Simona Capsoni; Jessica Franzot; Antonino Cattaneo; Enrico Cherubini
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

10.  Illicium sesquiterpenes: divergent synthetic strategy and neurotrophic activity studies.

Authors:  Lynnie Trzoss; Jing Xu; Michelle H Lacoske; William C Mobley; Emmanuel A Theodorakis
Journal:  Chemistry       Date:  2013-03-22       Impact factor: 5.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.